| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/01/2006 | EP1223953B1 Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1146894B1 Uses of thank protein, a tnf homologue, to inhibit growth of tumour cells |
| 02/01/2006 | EP1133315B1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 02/01/2006 | EP1129204B1 Novel system for regulating transgene expression |
| 02/01/2006 | EP1115849B1 Genes of the 1-desoxy-d-xylulose biosynthetic pathway |
| 02/01/2006 | EP1101819B1 GENE Any-RF, DORMANCY REGULATORY SUBSTANCE, PROCESS FOR PRODUCING THE SAME AND CELL REGULATOR FOR VITAL CELLS |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | EP1026243B1 NUCLEIC ACID CAPABLE OF BINDING SPECIFICALLY TO Ras TARGET PROTEIN |
| 02/01/2006 | EP1001804B1 Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections |
| 02/01/2006 | EP0969854B1 Inhibition of signal transduction by the binding of non-phosphorylated compositions |
| 02/01/2006 | EP0956040B1 Stimulation of host defense mechanisms against viral challenges |
| 02/01/2006 | EP0922056B1 New fibrinogen binding protein originating from coagulase-negative staphylococcus |
| 02/01/2006 | EP0907736B1 Cc-type chemokines |
| 02/01/2006 | EP0906119B1 Stimulation of host defense mechanisms against cancer |
| 02/01/2006 | EP0898478B1 Stimulation of host defence mechanisms against tumors |
| 02/01/2006 | EP0264434B2 Detection of a unique chlamydia strain associated with acute respiratory disease |
| 02/01/2006 | CN1729019A Wild-type RAD as a cancer therapeutic agent |
| 02/01/2006 | CN1729018A G-CSF conjugates |
| 02/01/2006 | CN1729017A A preparation and method for weight reduction |
| 02/01/2006 | CN1729016A Treatment of diabetes |
| 02/01/2006 | CN1729015A Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 02/01/2006 | CN1729014A Disease treatment via antimicrobial peptide inhibitors |
| 02/01/2006 | CN1729013A Broad spectrum anti-viral therapeutics and prophylaxis |
| 02/01/2006 | CN1729012A Method and composition for preventing and treating solid tumors |
| 02/01/2006 | CN1729011A Improved pharmaceutical botulinum toxin compositions |
| 02/01/2006 | CN1729010A The use of melagatran for the manufacture of a medicament for the treatment of type I diabetes mellitus |
| 02/01/2006 | CN1729009A Phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation |
| 02/01/2006 | CN1729008A Delocalization molecules and use thereof |
| 02/01/2006 | CN1728991A Combination therapy for the treatment of cancer |
| 02/01/2006 | CN1727480A Gene of expressing regeneration enhancement factor of recombined human liver in full lenght, and method for preparing regeneration enhancement factor of recombined human liver in full length, and usag |
| 02/01/2006 | CN1727479A Gene of expressing regeneration enhancement factor of recombined human liver in full length, and method for preparing regeneration enhancement factor of recombined human liver in full length, and usag |
| 02/01/2006 | CN1727014A Application of enkephalin of methionine, and method of application |
| 02/01/2006 | CN1727003A Carcinogen detoxification composition and method |
| 02/01/2006 | CN1727002A Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination |
| 02/01/2006 | CN1727001A Method of preparing system for controlled release of medication in protein category |
| 02/01/2006 | CN1726902A Combined formula and application of agent for stimulating growth of hair, and application |
| 02/01/2006 | CN1239713C Application of ion channel inhibitor for curing arhythmia |
| 02/01/2006 | CN1239516C Tumor necrosis factor relative cell death inducing ligand extracellular region mutation polypeptide and its prepn and use |
| 02/01/2006 | CN1239212C Device for percutaneous transdermal delivery having coated micro-protrusions |
| 02/01/2006 | CN1239207C Artificial biological canula and its making process |
| 02/01/2006 | CN1239201C Bone peptide for injection and its preparation method |
| 01/31/2006 | US6992207 Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| 01/31/2006 | US6992178 conferred to cultured animal cells and various tissues in the living bodies; contains a lectin; kits |
| 01/31/2006 | US6992174 Reducing the immunogenicity of fusion proteins |
| 01/31/2006 | US6992172 gels comprising hydroxylated amino acid sequences used as capsules, stabilizing agents, film-forming agents, moisturizers, emulsifiers, thickeners, colloids, adhesive agents, flocculants, coatings or carriers |
| 01/31/2006 | US6992171 Polypeptide and its DNA |
| 01/31/2006 | US6992170 Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
| 01/31/2006 | US6992169 Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. |
| 01/31/2006 | US6992108 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| 01/31/2006 | US6992105 N-[2-[(S)-2-Acetylthio-3-methylbutanoylamino]-2-methylpropionyl]-O-ben-zyl-L-serine Ethyl; inhibitors of angiotensin converting enzyme, neutral endopeptidase, endothelin converting enzyme. |
| 01/31/2006 | US6992081 Such as 4-((6-(3,5-difluoro-phenyl)-5-(S)-(3-dipropylcarb-amoyl-benzoyl-amino)-2-(R)-ethyl-4-(S)-hydroxy-hexanoylamino)-methyl)-cyclohexanecarboxylic acid for inhibiting secretase activity and cleavage of amyloid precursor protein |
| 01/31/2006 | US6992076 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals |
| 01/31/2006 | US6992070 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 01/31/2006 | US6992066 Povidone-containing carriers for polypeptide growth factors |
| 01/31/2006 | US6992065 Sustained release formulations |
| 01/31/2006 | US6992064 Central nervous system disorders; antidepressants |
| 01/31/2006 | US6992063 Compositions and method for regulating apoptosis |
| 01/31/2006 | US6992062 Method of stimulation hair growth |
| 01/31/2006 | US6992061 Removing endotoxin lipopolysacchardie from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica |
| 01/31/2006 | US6992060 Short term treatment with composition having gastrin/cholecystokinin receptor ligand and EGF receptor ligand, resulting in prolonged period of increased insulin release |
| 01/31/2006 | US6991936 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/31/2006 | US6991928 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis |
| 01/31/2006 | US6991920 Peptide for use in human therapeutics and diagnostics |
| 01/31/2006 | US6991916 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 01/31/2006 | US6991909 A novel protein, enkurin, that is preferentially expressed in sperm has been discovered. Enkurin binds to TRPCs including TRPC2-S, a protein encoded by TRPC2 that is not predicted to be a calcium channel subunit. The invention includes methods |
| 01/31/2006 | US6991908 Antiobestic agents methods for screening antiobestic agents and kits comprising same |
| 01/31/2006 | US6991901 Administering an antibody to the polypeptide sec1; angiogenesis inhibitors |
| 01/31/2006 | US6991817 Acid-modified arabinogalactan protein composition |
| 01/31/2006 | US6991810 a glycoprotein used as an industrial component such as an antifoulant, or an anti-adhesive, or as a pharmaceutical component such as an anti-inflammatory agent. |
| 01/31/2006 | US6991800 containing an echinocandin antifungal compound and an aqueous solvent, wherein the formulation includes about 20% w/v ethanol; extended shelf life, improved solubility |
| 01/31/2006 | US6991798 Compounds and compositions for delivering active agents |
| 01/31/2006 | US6991797 Immunogenic polypeptides derived from the short time culture filtrate of microbacterium tuberculosis; useful for the vaccination against infections caused by virulent Mycobacterium |
| 01/31/2006 | US6991796 Platlet glycoprotein IBα fusion polypeptides and methods of use thereof |
| 01/31/2006 | US6991794 FRIL family of factors and nucleic acids encoding the same; use as therapeutics for alleviating and/or reducing the hematopoietic progenitor cell-depleting activity of many cancer therapeutics |
| 01/31/2006 | US6991791 Administering anti- human tumor necrosis factor- alpha (TNF alpha) monoclonal antibody, or a TNF binding fragment for therapy of neurodegenerative disease in a human |
| 01/31/2006 | US6991789 modulating fusion between a lysosome and an endosome that carries the toxin in the cell; locally co-administering a toxin and a lysosome-endosome fusion inhibitor to a group of muscles of the patient in need thereof |
| 01/31/2006 | US6991788 Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| 01/31/2006 | US6991785 Administering by tissue absorption |
| 01/31/2006 | CA2490335C Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 01/31/2006 | CA2390104C Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins |
| 01/31/2006 | CA2346447C Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 01/31/2006 | CA2150803C Controlled release growth hormone containing microspheres |
| 01/30/2006 | CA2513936A1 Compositions and methods for treating skin conditions |
| 01/26/2006 | WO2006010155A2 Gonadotropin releasing hormone antagonists |
| 01/26/2006 | WO2006010143A2 Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| 01/26/2006 | WO2006010050A2 Modulation of synaptogenesis |
| 01/26/2006 | WO2006010004A2 Aequorin-containing compositions and methods of using same |
| 01/26/2006 | WO2006009902A2 Non-natural amino acids |
| 01/26/2006 | WO2006009890A2 Methods and compositions for producing insulin sensitization |
| 01/26/2006 | WO2006009825A1 Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| 01/26/2006 | WO2006009809A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 01/26/2006 | WO2006009801A2 Compositions and methods for treating central precocious puberty |
| 01/26/2006 | WO2006009764A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 01/26/2006 | WO2006009699A2 Targeting damaged lung tissue |
| 01/26/2006 | WO2006009682A2 Glue compositions for lung volume reduction |
| 01/26/2006 | WO2006009645A1 Methods of using macrocyclic modulators of the ghrelin receptor |
| 01/26/2006 | WO2006009533A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | WO2006009465A2 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009448A1 Anti-hypertensive functional food products |